Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 4.51% | 6,628.42% | -8.85% | 22.90% | -22.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.51% | 6,628.42% | -8.85% | 22.90% | -22.52% |
| Cost of Revenue | -97.14% | -26.47% | -14.25% | -10.39% | -69.17% |
| Gross Profit | 104.23% | 347.34% | 15.47% | 15.38% | 70.41% |
| SG&A Expenses | -34.38% | -22.07% | -16.06% | -17.59% | -0.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -83.54% | -25.54% | -14.70% | -11.88% | -63.74% |
| Operating Income | 88.28% | 276.67% | 15.64% | 15.89% | 64.75% |
| Income Before Tax | 98.99% | 252.20% | 12.23% | 27.50% | 60.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.99% | 252.20% | 12.23% | 27.50% | 60.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.99% | 252.20% | 12.23% | 27.50% | 60.77% |
| EBIT | 88.28% | 276.67% | 15.64% | 15.89% | 64.75% |
| EBITDA | 88.88% | 280.54% | 15.32% | 15.51% | 65.19% |
| EPS Basic | 99.53% | 174.62% | 48.92% | 52.22% | 75.99% |
| Normalized Basic EPS | 94.61% | 187.17% | 52.76% | 47.29% | 75.16% |
| EPS Diluted | 99.53% | 173.20% | 48.92% | 52.22% | 75.76% |
| Normalized Diluted EPS | 94.61% | 185.96% | 52.76% | 47.29% | 75.16% |
| Average Basic Shares Outstanding | 111.44% | 103.94% | 71.82% | 51.76% | 42.13% |
| Average Diluted Shares Outstanding | 111.44% | 106.76% | 71.82% | 51.76% | 42.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |